Clinical realities and economic considerations: Efficacy of intrathecal pain therapy

Judith A. Paice, Wolfhard Winkelmüller, Kim Burchiel, Gabor B. Racz, Joshua P. Prager

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Studies of analgesia in cancer patients have revealed that intrathecal administration of opioids can deliver potent analgesia with fewer systemic side effects than equivalent doses of systemic opioids. In addition, several trials have examined the safety and efficacy of this modality in patients with pain of nonmalignant origin. In one survey of 35 physicians involving 429 patients treated with intrathecal therapy, physician reports of global pain relief scores were excellent in 52.4% of patients, good in 42.9%, and poor in 4.8%. In another study of 120 patients, the mean pain intensity score had fallen from 93.6 to 30.5 six months after initiation of therapy. In both studies, patients reported significant improvement in activities of daily living, quality of life measures, and satisfaction with the therapy. Constipation, urinary retention, nausea, vomiting, and pruritus are typical early adverse effects of intrathecal morphine and are readily managed symptomatically. Other potential adverse effects include amenorrhea, loss of libido, edema, respiratory depression, and technical issues with the intrathecal system.

Original languageEnglish (US)
JournalJournal of Pain and Symptom Management
Volume14
Issue number3 SUPPL.
DOIs
StatePublished - Sep 1997

Fingerprint

Economics
Pain
Analgesia
Opioid Analgesics
Therapeutics
Physicians
Libido
Urinary Retention
Amenorrhea
Constipation
Pruritus
Activities of Daily Living
Respiratory Insufficiency
Morphine
Nausea
Vomiting
Edema
Quality of Life
Safety
Neoplasms

Keywords

  • Adverse effects
  • Analgesia
  • Intrathecal efficacy
  • Morphine
  • Naloxone
  • Neuropathic pain
  • Nociceptive pain
  • Opioids

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology
  • Neurology
  • Nursing(all)

Cite this

Clinical realities and economic considerations : Efficacy of intrathecal pain therapy. / Paice, Judith A.; Winkelmüller, Wolfhard; Burchiel, Kim; Racz, Gabor B.; Prager, Joshua P.

In: Journal of Pain and Symptom Management, Vol. 14, No. 3 SUPPL., 09.1997.

Research output: Contribution to journalArticle

Paice, Judith A. ; Winkelmüller, Wolfhard ; Burchiel, Kim ; Racz, Gabor B. ; Prager, Joshua P. / Clinical realities and economic considerations : Efficacy of intrathecal pain therapy. In: Journal of Pain and Symptom Management. 1997 ; Vol. 14, No. 3 SUPPL.
@article{92d894f7c5264c138cc1378f7eb09ef8,
title = "Clinical realities and economic considerations: Efficacy of intrathecal pain therapy",
abstract = "Studies of analgesia in cancer patients have revealed that intrathecal administration of opioids can deliver potent analgesia with fewer systemic side effects than equivalent doses of systemic opioids. In addition, several trials have examined the safety and efficacy of this modality in patients with pain of nonmalignant origin. In one survey of 35 physicians involving 429 patients treated with intrathecal therapy, physician reports of global pain relief scores were excellent in 52.4{\%} of patients, good in 42.9{\%}, and poor in 4.8{\%}. In another study of 120 patients, the mean pain intensity score had fallen from 93.6 to 30.5 six months after initiation of therapy. In both studies, patients reported significant improvement in activities of daily living, quality of life measures, and satisfaction with the therapy. Constipation, urinary retention, nausea, vomiting, and pruritus are typical early adverse effects of intrathecal morphine and are readily managed symptomatically. Other potential adverse effects include amenorrhea, loss of libido, edema, respiratory depression, and technical issues with the intrathecal system.",
keywords = "Adverse effects, Analgesia, Intrathecal efficacy, Morphine, Naloxone, Neuropathic pain, Nociceptive pain, Opioids",
author = "Paice, {Judith A.} and Wolfhard Winkelm{\"u}ller and Kim Burchiel and Racz, {Gabor B.} and Prager, {Joshua P.}",
year = "1997",
month = "9",
doi = "10.1016/S0885-3924(97)00167-X",
language = "English (US)",
volume = "14",
journal = "Journal of Pain and Symptom Management",
issn = "0885-3924",
publisher = "Elsevier Inc.",
number = "3 SUPPL.",

}

TY - JOUR

T1 - Clinical realities and economic considerations

T2 - Efficacy of intrathecal pain therapy

AU - Paice, Judith A.

AU - Winkelmüller, Wolfhard

AU - Burchiel, Kim

AU - Racz, Gabor B.

AU - Prager, Joshua P.

PY - 1997/9

Y1 - 1997/9

N2 - Studies of analgesia in cancer patients have revealed that intrathecal administration of opioids can deliver potent analgesia with fewer systemic side effects than equivalent doses of systemic opioids. In addition, several trials have examined the safety and efficacy of this modality in patients with pain of nonmalignant origin. In one survey of 35 physicians involving 429 patients treated with intrathecal therapy, physician reports of global pain relief scores were excellent in 52.4% of patients, good in 42.9%, and poor in 4.8%. In another study of 120 patients, the mean pain intensity score had fallen from 93.6 to 30.5 six months after initiation of therapy. In both studies, patients reported significant improvement in activities of daily living, quality of life measures, and satisfaction with the therapy. Constipation, urinary retention, nausea, vomiting, and pruritus are typical early adverse effects of intrathecal morphine and are readily managed symptomatically. Other potential adverse effects include amenorrhea, loss of libido, edema, respiratory depression, and technical issues with the intrathecal system.

AB - Studies of analgesia in cancer patients have revealed that intrathecal administration of opioids can deliver potent analgesia with fewer systemic side effects than equivalent doses of systemic opioids. In addition, several trials have examined the safety and efficacy of this modality in patients with pain of nonmalignant origin. In one survey of 35 physicians involving 429 patients treated with intrathecal therapy, physician reports of global pain relief scores were excellent in 52.4% of patients, good in 42.9%, and poor in 4.8%. In another study of 120 patients, the mean pain intensity score had fallen from 93.6 to 30.5 six months after initiation of therapy. In both studies, patients reported significant improvement in activities of daily living, quality of life measures, and satisfaction with the therapy. Constipation, urinary retention, nausea, vomiting, and pruritus are typical early adverse effects of intrathecal morphine and are readily managed symptomatically. Other potential adverse effects include amenorrhea, loss of libido, edema, respiratory depression, and technical issues with the intrathecal system.

KW - Adverse effects

KW - Analgesia

KW - Intrathecal efficacy

KW - Morphine

KW - Naloxone

KW - Neuropathic pain

KW - Nociceptive pain

KW - Opioids

UR - http://www.scopus.com/inward/record.url?scp=0343488396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0343488396&partnerID=8YFLogxK

U2 - 10.1016/S0885-3924(97)00167-X

DO - 10.1016/S0885-3924(97)00167-X

M3 - Article

C2 - 9291707

AN - SCOPUS:0343488396

VL - 14

JO - Journal of Pain and Symptom Management

JF - Journal of Pain and Symptom Management

SN - 0885-3924

IS - 3 SUPPL.

ER -